ClinicalTrials.gg
RecruitingNCT07853586Updated Nov 12, 2026

Ultrasound-guided Quadratus Lumborum Block Versus Erector Spinae Plane Block for Postoperative Analgesia in Children Undergoing Elective Open Lower Abdominal Surgeries

An interventional study of ultrasound guided anterior oudratus lumborum block and Ultrasound guided erector spinae plane block in Bilateral Inguinal Hernia Repair and Open Upper Abdominal Surgeries, sponsored by Menoufia University. Recruiting at 1 site in Egypt. Open to participants aged 2 Years to 7 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Menoufia University · Not applicable, Interventional, and Supportive care

How we know

Updated Nov 12, 2026Start date movedNewly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
2 Years to 7 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 45 studies in Hernia, Inguinal with a site in Egypt — 16 open to participants now, 17 under way, 1 of them phase 3. Hernia, Inguinal · Egypt.

Planned enrollment
19th of 43
60 · median 60
Started
2026
with 5 others
No phase
38 of 45
14 open now
Primary completion
2027-07
later than 15 of 16 live
Registered
40th of 45
by date

Among the 45 studies in Hernia, Inguinal with a site in Egypt, this one is the 19th largest by planned enrollment of the 43 interventional ones that give a count, is one of 6 that started in 2026, is one of 38 with no phase, reaches primary completion later than 15 of the 16 other live ones, and was the 40th registered.

Hernia, Inguinal

545 studies on the registry are indexed under Hernia, Inguinal; 91 are open to participants now.

Browse Hernia, Inguinal studies →

Open to participants now

16 of the 45 studies in Hernia, Inguinal with a site in Egypt are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 54 Hernia, Inguinal studies recruiting now, 30 (56%) set no upper age limit and 16 (30%) stop at 75 or younger; 16 take children under 18; 9 take healthy volunteers.

This study: 2 Years to 7 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies in Hernia, Inguinal with a site in Egypt, or all of them as a file.
02

Study summary

To compare the postoperative analgesic efficacy of ultrasound-guided Quadratus Lumborum Block (anterior approach) versus Erector Spinae Plane Block (T10-T12 level), both performed bilaterally with 0.25% bupivacaine (0.5 mL/kg per side), in the first 24 hours postoperatively in children undergoing elective open lower abdominal surgery under general anesthesia.

03

Conditions studied

  • Bilateral Inguinal Hernia Repair
  • Open Upper Abdominal Surgeries

Browse trials for

04

Who can participate

Ages eligible
2 Years to 7 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: 2 to 7 years.
  • ASA Physical Status Classification I or II .
  • Scheduled for elective minor open lower abdominal surgery (bilateral inguinal hernia repair, orchiopexy, circumcision, bilateral hydrocele repair), pyeloplasty and ureteric reimplantation.
  • Weight between 10 and 25 kg.

Exclusion criteria

Exclusion Criteria

  • Known allergy or to local anesthetics (amide class).
  • to regional anesthesia: coagulopathy ( > 1.5, \< 80,000/mm³), local infection at the injection site, or raised intracranial pressure.
  • Pre-existing neurological, neuromuscular, or spinal disorders.
  • Significant hepatic dysfunction ( Class B or C) or severe renal impairment ( \< 30 mL/min/1.73 m²).
  • Previous abdominal or retroperitoneal surgery which likely to distort fascial planes at the injection site.
  • Emergency or redo surgical procedures.
  • Inability to assess postoperative pain due to pre-existing developmental or cognitive impairment preventing validated pain scale use.
  • Intraoperative conversion from open to laparoscopic approach (post-randomization exclusion criterion).
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Ultrasound guided anterior quadratus lumborum block

    Procedure: ultrasound guided anterior oudratus lumborum block

  • Active comparator
    ultrasound guided erector spinae block

    Procedure: Ultrasound guided erector spinae plane block

Interventions

  • Procedureultrasound guided anterior oudratus lumborum block

    A high-frequency linear probe will be used to visualize the structures and a 22G, 80-mm echogenic needle will be inserted to deposit the drug. The probe will be placed above the iliac crest, and Petit's triangle will be identified. The three abdominal muscles (i.e., the external oblique, internal oblique, and transversus abdominus muscles) will be identified and will follow posteriorly until the layers of the Thoracolumbar Fascia (TLF) appeared as a bright hyper-echogenic line. The needle will be inserted in-plane along the posterior edge of the probe in anteromedial direction targeting the plane between the quadratus lumborum and psoas major muscle. After confirming the correct needle tip position and negative aspiration for blood, 0.5 mL/kg of 0.25% bupivacaine will be injected incrementally under real-time ultrasound guidance. The procedure will be repeated on the contralateral side.

  • ProcedureUltrasound guided erector spinae plane block

    The patient will be placed in the prone or lateral decubitus position. The ultrasound probe will be positioned para-sagittally approximately 2-3 cm lateral to the midline at the T10-T12 vertebral level. The T11 transverse process will be identified deep to the erector spinae muscle complex. Using an in-plane caudal-to-cranial approach, a 22-gauge echogenic needle will be advanced until the tip contacts the transverse process. Following confirmation of correct plane by injection of 0.5-1 mL saline creating hydrodissection between the erector spinae and transverse process, 0.5 mL/kg of 0.25% bupivacaine will be injected incrementally. The procedure will be repeated contralaterally \].

06

What researchers measure

Primary outcomes

  1. Time of first analgesic request

    Time frame: in the first 24 hours

Secondary outcomes

  1. total opioid (fentanyl equivalent) consumption /ug

    Time frame: the first 24 hours postoperatively

  2. postoperative pain intensity using the FLACC Scale (Face, Legs, Activity, Cry, Consolability) this scale range from 0to10 where 0 means no pain while 10 means worest untolerable pain

    Interpreting the Score * 0: Relaxed and comfortable * 1-3: Mild discomfort * 4-6: Moderate pain * 7-10: Severe pain or discomfort

    Time frame: 0, 30 minutes, 1, 2, 4, 6, 12, and 24 hours postoperatively.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

4 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Jul 2027, 8 months later.

Of 179 non-industry interventional studies with no phase under Hernia, Inguinal, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 35. This study's planned 8 months is below that.

Counting every sponsor, half of 188 studies reached it within 19 months; a quarter within 9 and three quarters within 36.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Nov 2026, on Nov 12, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2026
First posted
Oct 2, 2026
StartEst.
Nov 2026was Oct 2026
Primary completionEst.
Jul 2027
CompletionEst.
Jul 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 2026→Nov 2026
Nov 12, 2026
Secondary outcomes
Revised in 2 updates
What changed on Oct 6, 2026
  • Editedpostoperative pain intensity using the FLACC Scale (Face, Legs, Activity, Cry, Consolability) this scale range from 0to10Time frame: 0, 30 minutes, 1, 2, 4, 6, 12, and 24 hours postoperatively.
What changed on Oct 8, 2026
  • Editedpostoperative pain intensity using the FLACC Scale (Face, Legs, Activity, Cry, Consolability) this scale range from 0to10 where 0 means no pain while 10 means worest untolerable painTime frame: 0, 30 minutes, 1, 2, 4, 6, 12, and 24 hours postoperatively.
across 2 updates, Oct 6, 2026 – Oct 8, 2026
Registered
First appeared on the registry
Oct 2, 2026
Show all 4 updates
  1. Nov 12, 2026
    Start date Oct 2026→Nov 2026
  2. Oct 8, 2026
    Secondary outcomes 1 edited
    What changed in the outcomes
    • Editedpostoperative pain intensity using the FLACC Scale (Face, Legs, Activity, Cry, Consolability) this scale range from 0to10 where 0 means no pain while 10 means worest untolerable painTime frame: 0, 30 minutes, 1, 2, 4, 6, 12, and 24 hours postoperatively.
  3. Oct 6, 2026
    Secondary outcomes 1 edited
    What changed in the outcomes
    • Editedpostoperative pain intensity using the FLACC Scale (Face, Legs, Activity, Cry, Consolability) this scale range from 0to10Time frame: 0, 30 minutes, 1, 2, 4, 6, 12, and 24 hours postoperatively.
  4. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07853586
Responsible party
Nevine Mostafa Soliman (Assistant Professor, Menoufia University) — Principal investigator
First posted
Oct 2, 2026
Start date
Nov 2026 (estimated)
Primary completion
Jul 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

Nevine Soliman, MD
Contact
mostafanevine@gmail.com
201128861471

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion